NMRCCNew Mexico Radio Collectors Club
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
Contrary to the ASSURE trial, these observations indicated that among patients with high-risk clear-cell nmRCC after nephrectomy, the median DFS duration was significantly longer in the sunitinib group than in the placebo group: 6.8 years (95% CI, 5.8 to not reached) vs.
Taken together, the meta-analysis results failed to show any statistically significant DFS or OS benefit of adjuvant VEGFR TKI therapy in patients with high-risk nmRCC, when all three trials were considered.
The standard of care for nmRCC remains nephrectomy.
First, ASSURE examined sorafenib and sunitinib in the adjuvant setting after nephrectomy for nmRCC and both agents failed to demonstrate a DFS or OS benefit relative to placebo[1].